Scientific Health Development

McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.

Koya Medical, Inc. is a company based in Oakland, California, founded in 2018. It focuses on developing a connected wearable platform designed to address the significant unmet needs in the treatment of cancer-related chronic lymphedema and venous diseases. The technology aims to provide a drug-free solution for patients suffering from these conditions, enhancing their quality of life through innovative medical devices.

Empirical Spine, Inc. is a medical device company based in San Carlos, California, focused on developing innovative solutions for orthopedic and spinal surgery. Incorporated in 2015, the company specializes in a stabilization system designed to treat degenerative lumbar spinal disorders. Its flagship product, LimiFlex, is a minimally invasive flexion-restricting stabilization device that stabilizes the spine without compromising its function. This device is particularly beneficial for patients suffering from spinal stenosis with grade I degenerative spondylolisthesis, providing hospitals with effective tools for secure spinal surgeries.

Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Koya Medical, Inc. is a company based in Oakland, California, founded in 2018. It focuses on developing a connected wearable platform designed to address the significant unmet needs in the treatment of cancer-related chronic lymphedema and venous diseases. The technology aims to provide a drug-free solution for patients suffering from these conditions, enhancing their quality of life through innovative medical devices.

McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Sight Sciences, Inc. is a medical device company specializing in ophthalmic technologies for the treatment of prevalent eye diseases, including glaucoma and dry eye conditions. The company offers the OMNI Surgical System, which allows for the performance of canaloplasty and trabeculotomy through a single device and incision, effectively targeting intraocular pressure in patients with primary open-angle glaucoma. Additionally, Sight Sciences provides the TearCare System, a software-controlled wearable technology that delivers targeted thermal energy to the meibomian glands, addressing issues related to meibomian gland dysfunction and dry eye. Founded in 2010 and headquartered in Menlo Park, California, Sight Sciences serves both ophthalmologists and optometrists with its innovative product offerings.

Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.

AlgoMedica, Inc. is a medical imaging software company that specializes in developing technologies to reduce radiation exposure during CT scans. The company's flagship product, PixelShine, is a server or cloud-based software solution designed to enhance low-dose CT images, improving their quality to resemble images taken under standard radiation protocols. Utilizing artificial neural network technology, PixelShine can effectively process ultra-low dose images from various body parts, including the abdomen, pelvis, head, liver, and pediatrics. Founded in 2012, AlgoMedica is headquartered in Palo Alto, California, and aims to advance radiological practices by minimizing patient exposure to radiation while maintaining image quality.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

CureDM, Inc. is a biopharmaceutical company based in Wilmington, Delaware, focused on developing therapies aimed at preventing, ameliorating, or reversing diabetes. Founded in 2004, the company is working on innovative treatments that may allow patients with Type 1 and Type 2 diabetes to discontinue insulin use. One of its key product candidates is Pancreate, a human peptide therapeutic designed to regenerate insulin-producing islets in the pancreas. CureDM is dedicated to advancing solutions that address the significant challenges posed by diabetes.